Cellectis starts dosing patients in UCART123 ’s Phase I trial for BPDCN

Biopharmaceutical firm Cellectis has started dosing patients in a Phase I clinical trial of its universal chimeric antigen receptor T-cell (UCART) product candidate UCART123 to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news